RSSCOMPANIES: INDUSTRIES:
Biotechnology Jobs & Careers Search
Find your next job in Biotechnology. Search Biotechnology jobs from thousands of job and career search sites.
A search engine for jobs with a different approach to job and career searches. In one simple search, job
seekers get free access to millions of employment opportunities from thousands of websites. Find your next job in Biotechnology today.
Dako: New diagnostic tests provide hope for patients with stomach cancer
Dako announced that two of its products have obtained a CE-mark as diagnostic tests for selecting patients with metastatic stomach (gastric) cancer who may benefit from Herceptin(TM) treatment. ...
Biologics Sales 2009: Antibodies are the growth drivers
La Merie S.L. released the new compilation of biologics sales in 2009. In its fourth edition, the report showed again that cancer antibodies and anti-TNF antibodies were leading the field. Sales of ...
Desmoteplase enters clinical phase II in Japan in ischaemic stroke representing Lundbeck's first clinical programme in Japan
H. Lundbeck A/S announced the initiation of the first Japanese clinical phase II trial with desmoteplase (DIAS-J) in the treatment of acute ischaemic stroke. This study is required for the approval ...
Viron reports positive proof of concept results in arthritis for its VT-346 anti-TNF therapeutic
Viron Therapeutics Inc. announced that VT-346, an anti-TNF protein therapeutic, demonstrated positive results in a pivotal proof of concept study in the gold standard transgenic mouse model for ...
Study evaluates costs and benefits of new chemotherapy drugs
New chemotherapy agents appear associated with improvements in survival time for patients with metastatic colorectal cancer but at substantial cost. David H. Howard, PhD, and colleagues at Emory ...
Novartis: Exploratory trial shows no incremental benefit of aliskiren add-on therapy in improving changes to cardiac shape
The addition of the cardiovascular medicine aliskiren to standard therapy for patients recovering from a heart attack showed some positive effects in helping limit changes in the heart's shape and ...
Biogemma Licenses Yield and Drought Tolerance Genes from Evogene for Commercialization in Corn
Evogene Ltd. and Biogemma SAS announced the signing of a licensing agreement for the development and commercialization by Biogemma of hybrid corn lines, displaying improved yield and drought ...
UF researcher maps how age, gender can affect risk to radiation exposure
Doctors have a clearer picture than ever before of how much radiation reaches sensitive tissues during routine X-rays and similar imaging, thanks to sophisticated models of the human body being ...
Olink Genomics expands: New location and recruitment of CTO
Olink Genomics AB has recruited Fredrik Dahl as company CTO. Dr. Fredrik Dahl will lead the company R&D efforts, with focus on developing the Selector Technology and related products.Fredrik Dahl ...
Flanders and The Netherlands cooperate on biofuels from genetically modified poplars
Bio Base Europe is making progress in the development of sustainable biofuels. The recent first crop of genetically modified poplars of the Flemish Institute for Biotechnology (VIB) will be modified ...
Lactic bacteria fermentation for reducing the need for additives
VTT has developed a method whereby the use of additives in bread can be reduced significantly. At the same time, the taste and lightness of wheat bread made using sourdough, and keeping it soft ...
Novartis: NAVIGATOR shows valsartan delayed progression to type 2 diabetes in at-risk cardiovascular patients
Results from a landmark study involving more than 9,000 people showed that the high blood pressure medicine valsartan delayed progression to type 2 diabetes in patients with cardiovascular disease or ...
Nutri Pharma's Vacc-C5 to be prepared for phase I/II clinical trial
Based on encouraging results from pre-clinical research, Nutri Pharma ASA's wholly owned subsidiary Bionor Immuno AS, has announced that it will take the therapeutic and potentially preventative ...
Merck strengthens biorefineries of the future
In early March, the EU research project known as EuroBioRef was launched. Over the next four years, 28 partners from 14 countries will jointly develop future-oriented solutions for the ...
Crucell's Supervisory Board Nominates Mr. W. Burns, Mr. J. Shannon and Mr. G. Siber as New Board Members
Crucell N.V. announced the nomination of Mr. William (Bill) Burns, Mr. James Shannon and Mr. George Siber to join its Supervisory Board. The Supervisory Board of Crucell has nominated Mr. Burns, Mr. ...
How muscle cells control fatty acid uptake
A new study from the Swedish medical university Karolinska Institutet shows that the blood vessels and muscles of the heart can regulate the uptake of fatty acids that we ingest through meat, milk ...
Light activated 'warhead' turns modest molecules into super protein killers
Using a novel light activation technique, Scripps Research Institute scientists have been able to turn molecules with only a modest ability to fight specific proteins into virtual protein destroyers. ...
New microscopy technique offers close-up, real-time view of cellular phenomena
For two decades, scientists have been pursuing a potential new way to treat bacterial infections, using naturally occurring proteins known as antimicrobial peptides (AMPs). Now, MIT scientists have ...
MorphoSys Granted Further Patent on its Core Antibody Technology in Japan
MorphoSys AG announced that the Japanese Patent Office has granted a new patent providing extended protection for the Company's core technology HuCAL. The new patent (JP 4436457) covers the ...
A golden bullet for cancer
In a lecture he delivered in 1906, the German physician Paul Ehrlich coined the term Zauberkugel, or "magic bullet," as shorthand for a highly targeted medical treatment. Magic bullets, also called ...
Bionity.COM News
The latest news about trends and developments in the biotech, pharma and life science industries
Human Genome Sciences, Inc. Lung Cancer Drug, Mapatumumab in Combination with Chemotherapy Agents Fails to Improve Survival
ROCKVILLE, Md., Mar 17, 2010 (BUSINESS WIRE) -- Human Genome Sciences, Inc. /quotes/comstock/15*!hgsi/quotes/nls/hgsi (HGSI 31.25, -0.46, -1.45%) today announced the results of its randomized Phase 2 trial of mapatumumab (HGS-ETR1) in combination with the chemotherapy agents paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC).
The results showed...
Pfizer Inc. to Make Bid for Ratiopharm Today
Reuters -- Pfizer (PFE.N) will on Wednesday place an offer in the final round of bids for German generic drug maker Ratiopharm, a person briefed on the matter told Reuters on Wednesday.
Women More Likely To Die After Heart Attack, Study
ATLANTA, March 16 (Reuters) - When it comes to matters of the heart, women should be treated more like men.
The Medicines Company Expands a Nationwide Recall for Certain Lots of Cleviprex(R) That May Contain Particulate Matter
PARSIPPANY, NJ--(Marketwire - 03/17/10) - The Medicines Company (NASDAQ:MDCO - News) announced today that it is voluntarily expanding the recall of Cleviprex (clevidipine butyrate) injectable emulsion due to the potential presence of visible particulate matter which has been observed in some vials. Four (4) additional lots of Cleviprex are being recalled. The four additional Cleviprex lots are ...
Abraxis BioScience, Inc.: ABRAXANE Meets Primary Endpoint in Phase 3 Trial for Advanced Non-Small Cell Lung Cancer
LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABII - News) today announced that its randomized registrational Phase 3 clinical trial comparing ABRAXANE (protein-bound paclitaxel) with Taxol (paclitaxel) injection, both in combination with carboplatin, met the studys primary endpoint by demonstrating that ABRAXANE showed a significant improvement in overall response rate as compared...
Antidepressants Can Help People With Physical Ills, King's College London Study
LONDON (Reuters) - Antidepressants such as Eli Lilly's Prozac or GlaxoSmithKline's Paxil can help depressed patients with physical illness, and doctors should consider them more often, researchers said on Wednesday.
New Radiation Therapy Shows Promise In Lung Cancer, University of Texas Southwestern Medical Center Study
CHICAGO (Reuters) - Aiming powerful beams of radiation precisely at tumors helped control their growth and helped people with early stage but inoperable lung cancer live longer, U.S. researchers said on Tuesday.
Hint of Chemoprevention Potential for Lynch Syndrome, M. D. Anderson Cancer Center Study
MedPage Today -- SAN FRANCISCO -- Oral contraceptives and medroxyprogesterone acetate (MPA, DepoProvera) may have potential as chemopreventive agents for endometrial cancer in women with Lynch syndrome, biomarker data from a small randomized trial suggest.
Trials Show Effectiveness Of Ablation Over Drugs In AF, Mayo Clinic Study
MedPage Today -- ATLANTA -- Catheter ablation appears better than drug therapy for more complex, symptomatic atrial fibrillation, according to initial results of the CABANA pilot trial.
Potential New Drug for Type 2 Diabetes, Ohio State University Study
Ohio State University -- COLUMBUS, Ohio An experimental oral drug has lowered blood sugar levels and inflammation in mice with Type 2 diabetes, suggesting that the medication could someday be added to the arsenal of drugs used by millions of Americans with this disease, according to new research.
Could Cancer Win The War?
MedPage Today -- Almost 40 years and 100 billion federal dollars have been invested in the "War on Cancer" since President Richard M. Nixon declared it, but the campaign is far from over, two researchers concluded this week in the Journal of the American Medical Association.
U.S. FDA Warns Glenmark Pharmaceuticals on Unapproved Drug
Reuters -- Glenmark Pharmaceuticals Ltd (GLEN.BO) sold nitroglycerin tablets without approval from U.S. regulators, the Food and Drug Administration said in a letter released on Tuesday.
Acetaminophen Alone Works Well for Postpartum Pain, Study in Study
Newswise For many mothers of newborns, lingering pain from the delivery can interfere with their first days with their infant. A recent review examined whether over-the-counter medications containing acetaminophen Tylenol for example - provided adequate relief for such pain and concluded that they are effective.
Level of Gene Alters Risk of Alzheimer's Disease, Mayo Clinic Researchers Find
Mayo Clinic -- JACKSONVILLE, Fla. Using sophisticated techniques that scan the genomes of patients, researchers at the Mayo Clinic campus in Florida have found that a gene appears to either help protect against development of Alzheimer's disease, or promote the disorder depending on the level of gene in the brain.
Novartis Pharma AG Reports Positive Results From Phase II LCZ696 Trial
Novartis Pharma has reported that its investigational product LCZ696, an angiotensin receptor neprilysin inhibitor (ARNI), has successfully completed its first large-scale clinical trial, highlighting the potential of the compound in the treatment of hypertension and other cardiovascular diseases.
LCZ696 is a novel-acting compound with distinctive chemical and biological properties; upon...
Prometheus Laboratories Inc. and Bayer Schering Pharma to Apply Novel Diagnostic Platform to Oncology Therapeutic Candidates; Eligible for Upfront and Milestone Payments up to $160 Million
SAN DIEGO, March 17 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the execution of a research collaboration and license agreement with Bayer Schering Pharma AG, Germany, a worldwide leading specialty pharmaceutical company. The collaboration partners Prometheus' proprietary oncology diagnostic platform with Bayer's broad oncology pipeline...
University of Michigan Scientists Identify Chemical In Bananas As Potent Inhibitor Of HIV Infection
Newswise A potent new inhibitor of HIV, derived from bananas, may open the door to new treatments to prevent sexual transmission of HIV, according to a University of Michigan Medical School study published this week.
Novel Stroke Treatment Passes Safety Stage of Clinical Trial At University of California, Irvine Study
ScienceDaily (Mar. 11, 2010) A clinical research trial of a new treatment to restore brain cells damaged by stroke has passed an important safety stage, according to the UC Irvine neurologist who led the effort.
Movement Disorder Symptoms Are Lessened by an Antibiotic, University of Alabama at Birmingham Study
EurekAlert! -- TUSCALOOSA, Ala. Discovery of an antibiotic's capacity to improve cell function in laboratory tests is providing movement disorder researchers with leads to more desirable molecules with potentially similar traits, according to University of Alabama scientists co-authoring a paper publishing March 10 in the journal Disease Models & Mechanisms.
Unigene Laboratories, Inc. Receives Additional Capital in Debt Restructuring; Begins to Revamp Management Team
BOONTON, N.J.--(BUSINESS WIRE)--Unigene Laboratories, Inc. (OTCBB: UGNE, http://www.unigene.com) today announced that it has entered into an amended and restated financing agreement for $33 million three-year convertible senior secured term notes. At the closing, which is scheduled to occur today, Unigene will issue $33,000,000 of new convertible senior secured notes due in 2013, in exchange for approximately...
Molecular Insight Pharmaceuticals, Inc. Says Gets Going Concern Warning from Auditors
Reuters -- Molecular Insight Pharmaceuticals Inc posted a narrower-than-expected quarterly loss, but said its auditors have expressed doubts on its ability to continue as a going concern, partly due to recurring losses from its operations.
King Pharmaceuticals??, Inc. Unit, Alpharma Inc. to Pay $42.5 Million Over Kadian Claims
Reuters -- Alpharma Inc, a unit of King Pharmaceuticals (KG.N), has agreed to pay $42.5 million to resolve allegations that it gave kickbacks to doctors to prescribe the pain drug Kadian and misrepresented its safety and effectiveness, the Justice Department said on Tuesday.
Sanofi-Aventis (France) Says World Health Organization Suspension of Shan5 Is Precautionary Measure
Bloomberg -- Sanofi-Aventis SA said the World Health Organizations temporary suspension of its Shan5 vaccine is a precautionary measure pending outcome of an investigation of vaccine quality.
Baldness 'Could Be Good For Your Health' Say University of Washington Scientists
BBC News -- A receding hairline can be a good thing, according to US scientists, who say men who go bald by 30 appear to be less likely to develop prostate cancer.
Eli Lilly and Company Gets Rights to Sell Testosterone Drug from Acrux Limited in Deal Worth up to $335 Million
INDIANAPOLIS and MELBOURNE, Australia, March 15 /PRNewswire-FirstCall/ -- Eli Lilly and Company and Acrux announced today that they have entered into an exclusive worldwide license agreement for the potential commercialization of Acrux's experimental underarm testosterone solution (proposed tradename AXIRON(TM)). The new drug application for AXIRON is currently under regulatory...
Some Antidepressants May Raise Cataract Risk, University of British Columbia Study
NEW YORK (Reuters Health) - People who take certain drugs for depression known as selective serotonin reuptake inhibitors (SSRIs) may have a higher-than-average risk of developing cataracts, a study from Canada hints.
Dynavax Technologies Corporation Gets Going-Concern Warning; Auditors Express Doubts on Company's Financial Position
Reuters -- Dynavax Technologies Corp (DVAX.O) said its auditors have expressed doubts on the company's ability to continue as a going concern as a result of the company's current financial position.
New Anticoagulants Signal Start of Post-Warfarin Era, American College of Cardiology President Says
MedPage Today -- ATLANTA -- Atrial fibrillation is both a major stroke risk and a looming public health problem since the risk of afib increases with age, and the standard treatment, warfarin, is often a clinical management challenge. But a number of investigational therapies suggest that a post-warfarin era is beginning.
Proton-Pump Inhibitor Plus Clopidogrel Is Less Likely to Cause Bleeding Ulcers, Vanderbilt University Study
Newswise Heart patients who took a stomach acid-suppressing proton-pump inhibitor along with clopidogrel a drug that prevents blood clots were only half as likely to be hospitalized for upper digestive tract bleeding than those who used clopidogrel alone, according to a new study supported by HHS Agency for Healthcare Research and Quality and the National Heart, Lung, and Blood Institute at...
Medivation, Inc. Loses $54.8 Million in 2009
SAN FRANCISCO, March 15 /PRNewswire-FirstCall/ -- Medivation, Inc. today provided a corporate update and reported its financial results for the year ended December 31, 2009. "We are disappointed by the results of the Phase 3 CONNECTION trial in Alzheimer's patients, and it is our highest priority to work with our colleagues at Pfizer to further analyze the data and determine next steps...
AstraZeneca PLC Says Will be Picky in Emerging Markets
Reuters -- AstraZeneca (AZN.L) expects double-digit growth in emerging markets, the new battleground for Big Pharma as sales in Western markets stall, but said on Tuesday it would be much more selective than some of its rivals.
Women Seek Neck Muscle Lip Implants For Plumper Pouts, Says
BBC News -- Forget the collagen, for the perfect pout plump for a lip graft using muscle from your neck, according to US cosmetic surgeons.
University of Essex Scientists Make Important Discovery in Gene Regulation
ScienceDaily (Mar. 11, 2010) Scientists at the University of Essex have a greater understanding of how our genes are controlled following a major research project.
Genetix Pharmaceuticals, Inc. Secures $35 Million in Series B Funding
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genetix Pharmaceuticals, a leading gene therapy company developing breakthrough treatments for severe genetic disorders, announced today that it has completed a $35 million Series B financing with new investors Third Rock Ventures and Genzyme Ventures joining TVM Capital, Forbion and Easton Capital. Proceeds from the financing will be used to advance current clinical...
University of Iowa Research Points to Way to Improve Heart Treatment
University of Iowa -- Current drugs used to treat heart failure and arrhythmias (irregular heartbeat) have limited effectiveness and have side effects. New basic science findings from a University of Iowa study suggest a way that treatments could potentially be refined so that they work better and target only key heart-related mechanisms.
Calcium May Help You Live Longer, Karolinska Institute Study
NEW YORK (Reuters Health) - Getting a bit more calcium in your diet could help you live longer, new research suggests.
4-Antibody AG Announces a Long-Term Collaboration With Boehringer Ingelheim Corporation for Therapeutic Antibodies; will Receive Payments of up to EUR 177.5 Million
BASEL, Switzerland, March 16, 2010 /PRNewswire/ -- 4-Antibody AG today announces a major long-term collaboration with Boehringer Ingelheim to discover and to develop fully human therapeutic antibodies for a number of targets in various disease indications. 4-Antibody will use its proprietary and unencumbered Hu-PAC(R) and Retrocyte Display(R) technologies for the discovery and development of fully...
US FDA Warns ISTA Pharmaceuticals, Inc. on Claims in Xibrom Eye Drug Promotion
Reuters -- Ista Pharmaceuticals Inc (ISTA.O) made misleading claims about Xibrom eye solution in sales material, U.S. regulators said in a letter released on Tuesday.
Erectile Dysfunction Is Strong Predictor Of Fatal Heart Ailments, University of Saarland Study Finds
LA Times -- Men treated for ED should routinely be checked for cardiovascular problems, experts say. For the first time, researchers have shown that erectile dysfunction is a strong predictor of the likelihood that men will die of heart disease.
Heist Nets $75 Million in Eli Lilly and Company Drugs
WTNH -- Police are investigating an over-the-weekend drug heist at a Connecticut warehouse filled with prescription drugs. Investigators say it appears a group of people broke into the building and stole up to $75 million worth of prescription drugs.
Stem Cells Build New Blood Vessels To Treat Peripheral Arterial Disease, Johns Hopkins University School of Medicine Study
EurekAlert! -- TAMPA, Fla. (March 16, 2010)Bone marrow stem cells suspended in X-ray-visible microbubbles dramatically improve the body's ability to build new blood vessels in the upper legproviding a potential future treatment for those with peripheral arterial disease or PAD, say researchers at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.
One Gene Lost = One Limb Regained? The Wistar Institute Scientists Demonstrate Mammalian Regeneration Through a Single Gene Deletion
The Wistar Institute -- PHILADELPHIA (March 15, 2010) A quest that began over a decade ago with a chance observation has reached a milestone: the identification of a gene that may regulate regeneration in mammals. The absence of this single gene, called p21, confers a healing potential in mice long thought to have been lost through evolution and reserved for creatures like flatworms, sponges, and...
New Avenue for Developing Treatments for Genetic Muscle-Wasting Disease, Ottawa Health Research Institute Study
Ottawa Health Research Institute -- Scientists from the Ottawa Hospital Research Institute (OHRI) and the University of Ottawa have identified a promising new approach for developing drugs to treat Spinal muscular atrophy (SMA), the leading inherited cause of death in infants and toddlers. Dr. Rashmi Kothary and his doctoral student Melissa Bowerman have found that an enzyme called RhoA is overly active...
Novartis Corporation's Drug Tekturna Fails to Help After Heart Attack According to Study
Reuters -- The addition of the Novartis (NOVN.VX) blood pressure medicine Tekturna to current standard drugs in patients who had a heart attack failed to help prevent changes in the heart's shape and worsening of its blood pumping ability, according to data from a study.
Bt Protein Found Effective Against Parasitic Roundworm Infections, University of California, San Diego (UCSD) Study
ScienceDaily (Mar. 16, 2010) Biologists at UC San Diego have discovered that a protein from a soil bacterium used to kill insects naturally on organic crops is a highly effective treatment for intestinal parasitic roundworms. These parasites, which include hookworms and whipworms, infect about two billion people in underdeveloped tropical regions and are cumulatively one of the leading causes of...
Promedior Closes $12 Million Series C Financing
MALVERN, Pa.--(BUSINESS WIRE)--Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat inflammatory and fibrotic diseases, today announced that it has raised $12 million in a Series C financing round. Forbion Capital Partners led the round, with participation from existing investors Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, and Easton...
Tekmira Pharmaceuticals Corporation and Pfizer Inc. Initiate New Research Collaboration
VANCOUVER, BRITISH COLUMBIA--(Marketwire - 03/16/10) - Tekmira Pharmaceuticals Corporation (TSX:TKM - News), a leading developer of RNA interference (RNAi) therapeutics, announced today the initiation of a new research collaboration with Pfizer (NYSE:PFE - News).
Tekmira and Pfizer will collaborate on evaluating Tekmira's stable nucleic acid-lipid particle (SNALP) technology to deliver small...
FDA Delays Approval of Amylin Pharmaceuticals, Inc., Eli Lilly and Company Diabetes Drug; Requests Finalization of Product Labeling
SAN DIEGO, INDIANAPOLIS, and WALTHAM, Mass., March 15, 2010 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq:AMLN - News), Eli Lilly and Company (NYSE:LLY - News) and Alkermes, Inc. (Nasdaq:ALKS - News) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for BYDUREON (exenatide for extended-release...
Novartis Corporation Drugs Fail to Help High-Risk Patients
Reuters -- The Novartis (NOVN.VX) diabetes drug Starlix failed to reduce progression to the disease or cut down on serious heart problems in patients at high risk for both diabetes and heart disease, according to a large study released on Sunday.
SSRI, Naltrexone, Talk Therapy Keep Depressed Alcoholics Dry, University of Pennsylvania Study
MedPage Today -- Combining sertraline (Zoloft) and the opioid antagonist naltrexone better than either drug alone or placebo in keeping depressed alcoholics sober, researchers said.
Tumor Surgery Impairs Sexuality, Study in Deutsches ??rzteblatt International
EurekAlert! -- Sexual problems are frequent after operations for carcinoma of the rectum. Christian Schmidt et al. describe the consequences for quality of life in the current issue of Deutsches rzteblatt International (Dtsch Arztebl Int 2010; 107[8]: 123-30).
FDA Requests Additional Information Regarding AFREZZA in Complete Response Letter to MannKind Corporation
VALENCIA, Calif.--(BUSINESS WIRE)--MannKind Corporation (Nasdaq:MNKD - News) today announced that it has received a Complete Response letter from the U.S. Food & Drug Administration (FDA) regarding the New Drug Application (NDA) for AFREZZA (insulin human [rDNA origin]) Inhalation Powder for the treatment of adult patients with type 1 and type 2 diabetes mellitus for the control of hyperglycemia...
Rosuvastatin Plus Fenofibric Acid Treatment Maintains Potency; Improves Lipid Profile, Baylor College of Medicine Study At American College of Cardiology Conference
MedPage Today -- ATLANTA -- Two years after beginning lipid-lowering therapy with an investigative treatment combining rosuvastatin (Crestor) with fenofibric acid (Trilipix), patients maintained an improved lipid profile without new adverse effects, researchers said.
No Heart Benefit Seen With Fibrates In Diabetics, National Institutes of Health (NIH) Study
ATLANTA (Reuters) - Adding a triglyceride-lowering drug to cholesterol-fighting statins provided no additional protection from heart attack, stroke and death from heart disease in patients with Type 2 diabetes, according to data from a large study.
Effort Aims to Spike Breast Cancer With New Approach, And Translational Genomics Research Institute (TGen) Study
SCOTTSDALE, Ariz. - March 11, 2010 - Many women live with breast cancer that does not respond to standard medical treatment, a condition that researchers at the Virginia G. Piper Cancer Center at Scottsdale Healthcare want to change by aggressively targeting specific genes.
NGM Biopharmaceuticals, Inc. Raises $51 Million in Series B Financing and Appoints New Board Member
SOUTH SAN FRANCISCO, Calif., March 15 /PRNewswire/ -- NGM Biopharmaceuticals today announced it has closed the first tranche of a $51 million Series B round of financing. The Series B round included The Column Group, Tichenor Ventures, LLC, Prospect Venture Partners, Rho Ventures and other new and Series A investors. With this financing, NGM also announced the appointment of McHenry (Mac) T. Tichenor...
New Clues About the Basis of Muscle Wasting Disease, Study
ScienceDaily (Mar. 14, 2010) New findings that shed light on how genetic damage to muscle cell proteins can lead to the development of the rare muscle-wasting disease, nemaline myopathy, are reported March 15 in the Biochemical Journal.
OSI Pharmaceuticals, Inc. Board Rejects Astellas Pharma Inc. $3.5 Billion Bid
MELVILLE, N.Y., Mar 15, 2010 (BUSINESS WIRE) -- --Board Recommends Stockholders Not Tender Shares at $52.00 per Share
--Company, With Assistance of Financial Advisors, to Contact Third Parties
OSI Pharmaceuticals, Inc. /quotes/comstock/15*!osip/quotes/nls/osip (OSIP 58.34, 0.66, 1.14%) today announced that its Board of Directors, after careful review and consideration with the...
Ablynx Successfully Raises E 50 Million With Secondary Public Offering
GHENT, BELGIUM--(Marketwire - 03/15/10) - This announcement is an advertisement and not a prospectus. Investors should not subscribe for or purchase any securities referred to in this announcement except on the basis of information in the prospectus published by Ablynx NV (the "Company") on 26 February 2010 (which is supplemented by an addendum approved by the CBFA on 7 March 2010) in connection with...
Rhythm Pharmaceuticals Announces $21 Million Series A
BOSTON, March 15 /PRNewswire/ -- Rhythm Pharmaceuticals (Rhythm), a biotechnology company developing peptide therapeutics for metabolic diseases, announced today that it has completed the first close on its Series A equity financing of $21 million. The financing was led by MPM Capital (MPM) and New Enterprise Associates (NEA). The funds will be used to develop products licensed from Ipsen (Euronext...
Bristol-Myers Squibb Company , Sanofi-Aventis (France)'s Plavix Gets New U.S. FDA Warning
BRIDGEWATER, N.J. & PRINCETON, N.J.--(BUSINESS WIRE)--Sanofi-aventis U.S. and Bristol-Myers Squibb Company (NYSE: BMY - News) today announced revisions to the U.S. prescribing information for PLAVIX (clopidogrel bisulfate), which include a boxed warning. The boxed warning concerns the diminished effectiveness of PLAVIX in patients who have a genetic variation leading to reduced formation of the active...
Inspire Pharmaceuticals, Inc. Eye Drug, Azasite Fails in Mid-Stage Study
Reuters -- Inspire Pharmaceuticals Inc (ISPH.O) said its experimental eye drug, Azasite, failed to meet the main goals of two mid-stage trials.
Ex-Schering-Plough Corporation Executives Take Reins at Bausch & Lomb; New CEO
ROCHESTER, NY--(Marketwire - 03/15/10) - Bausch Lomb has named Fred Hassan as chairman of the Board of Directors and has named Brent Saunders as chief executive officer and appointed him to the Board of Directors, effective immediately.
Current Chairman and CEO Gerald M. Ostrov is retiring, and will serve as a consultant to the new leaders.
Mr. Hassan is one of the leading figures...
Merck & Co., Inc., Portola Pharmaceuticals, Inc. Blood Thinner Appears Safe, Effective-Study
ATLANTA--(BUSINESS WIRE)--Portola Pharmaceuticals and Merck today announced the results of EXPLORE-Xa, a Phase 2 exploratory, dose finding study of betrixaban, an investigational oral direct Factor Xa inhibitor. Results showed that a once-daily dose of oral betrixaban, given to patients with non-valvular atrial fibrillation or atrial flutter and at least one risk factor for stroke, reduced the incidence...
Mylan Inc. Pulls EU Application for Generic Taxotere
Reuters -- Mylan (MYL.O) has withdrawn its application to market a generic version of Sanofi-Aventis's (SASY.PA) cancer drug in Europe, after adverse feedback from regulators.
MiddleBrook Pharmaceuticals, Inc. Plans Massive Layoffs, CEO Resigns
Reuters -- MiddleBrook Pharmaceuticals Inc (MBRK.O) said its auditors have expressed doubts on the company's ability to continue as a going concern and that it was evaluating strategic options, which may include selling itself.
Stem Cell Research Shows Promise for Tissue-Engineered Vascular Grafts, Northwestern University Study
ScienceDaily (Mar. 14, 2010) The promise of stem cells lies in their unique ability to differentiate into a multitude of different types of cells. But in order to determine how to use stem cells for new therapeutics, scientists and engineers need to answer a fundamental question: if a stem cell changes to look like a certain type of cell, how do we know if it will behave like a certain type of cell...
Genome Institute of Singapore Scientists Make Groundbreaking Discovery Of Genes That Increase The Likelihood Of Causing A Form Of Inflammatory Bowel Disease
Researchers at the Genome Institute of Singapore (GIS), Associate Director for Infectious Diseases Dr Martin Hibberd and Assoc Prof Mark Seielstad; and the Karolinska Institutet (KI) in Stockholm, Sweden, Assoc Prof Leif Trkvist, Assoc Professor Mauro DAmato and Prof Sven Pettersson, have collaborated with research teams from the USA, the Netherlands, and Italy to identify genes increasing the likelihood...
Pfizer Inc. Discontinues A Phase 3 Study Of Figitumumab In Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today the discontinuation of A4021018 (also known as ADVIGO 1018), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) in combination with erlotinib as a second/third-line treatment in patients with previously treated advanced non-adenocarcinoma non-small cell lung cancer (NSCLC). An independent Data Safety Monitoring...
Pfizer Inc. Says Sutent Breast Cancer Trials Fail
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that two Phase 3 studies of Sutent (sunitinib malate) in advanced breast cancer did not meet their primary endpoints. The SUN 1064 Phase 3 study of sunitinib in combination with docetaxel for the first-line treatment of patients with advanced HER-2 negative breast cancer did not show a statistically significant improvement in progression-free...
Roche Holding AG, Genentech (South SF)'s Avastin Fails in Prostate Cancer Study
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today the topline results of a Phase III trial led by the U.S. Cancer and Leukemia Group B (CALGB) and sponsored by the National Cancer Institute (NCI) investigating the use of Avastin (bevacizumab) in combination with docetaxel chemotherapy and prednisone...
Breast Cancer Drug Fulvestrant Appears More Effective in the Presence of CK8 and CK18, Indiana University Study
ScienceDaily (Mar. 12, 2010) Women's responsiveness to the second-line breast cancer drug fulvestrant may depend on whether the cancer cells are expressing two key proteins, Indiana University Bloomington scientists report in this month's Cancer Biology & Therapy.
Ipsen Grants Rhythm Pharmaceuticals Obesity Treatment Licence; will Receive up to $80 Million
PARIS & BOSTON--(BUSINESS WIRE)--Regulatory News: Ipsen (Paris:IPN - News) (Euronext: FR0010259150; IPN), a global biotechnology specialty care group, and Rhythm Pharmaceuticals (Rhythm), a biotechnology company developing peptide therapeutics for metabolic diseases, announced today that they have concluded a license agreement for Ipsens proprietary peptide therapeutics targeting obesity, metabolic...
AVEO Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO - News), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the pricing of its initial public offering of 9,000,000 shares of its common stock at $9.00 per share, before underwriting discounts and commissions. All of the common stock is being offered by AVEO...
FDA Approves Watson Pharmaceuticals, Inc.'s TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer
MORRISTOWN, N.J., March 11 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI - News), today announced the U.S. Food and Drug Administration (FDA) approval of TRELSTAR 22.5 mg (triptorelin pamoate for injectable suspension), a new twice-yearly formulation of TRELSTAR, a proven, simple and effective palliative treatment of advanced prostate cancer. With an anticipated May launch, TRELSTAR...
TaiGen Biotechnology Announces Nemonoxacin (TG-873870) Once-A-Day Oral Dosing in Diabetic Foot Infection Met Primary Endpoints
TAIPEI, Taiwan, March 12 /PRNewswire-Asia/ -- TaiGen Biotechnology Co., Ltd. announced today the Phase II trial of nemonoxacin (TG-873870) in Diabetic Foot Infection (DFI) with once-a-day dosing met the primary endpoints and showed promising clinical efficacy and good tolerability. Nemonoxacin is a novel non-fluorinated quinolone that has a broad spectrum of activity against gram-positive and...
Sanofi-Aventis K.K. And Bristol-Myers Squibb Company Announce Important Updates to PLAVIX U.S. Prescribing Information; FDA Announces New Boxed Warning on Plavix
BRIDGEWATER, N.J. & PRINCETON, N.J.--(BUSINESS WIRE)--Sanofi-aventis U.S. and Bristol-Myers Squibb Company (NYSE: BMY) today announced revisions to the U.S. prescribing information for PLAVIX (clopidogrel bisulfate), which include a boxed warning. The boxed warning concerns the diminished effectiveness of PLAVIX in patients who have a genetic variation leading to reduced formation of the active metabolite...
Progenics Pharmaceuticals, Inc. to Advance Oral Methylnaltrexone into Late Stage Clinical Development
TARRYTOWN, N.Y.--(BUSINESS WIRE)--Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX - News) today announced that it plans to advance oral methylnaltrexone for the treatment of opioid-induced constipation (OIC) into late stage clinical development and will commence a phase 2b/3 clinical trial of a methylnaltrexone tablet in chronic-pain patients in the second half of 2010. Progenics also announced data...
Ligand Pharmaceuticals Inc. Announces Approval for GlaxoSmithKline's Revolade(R) in Europe
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that GlaxoSmithKline (NYSE: GSK) was granted marketing authorization from the European Commission (EC) for Revolade (eltrombopag) for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP). Eltrombopag is...
Azur Pharma Inc. to Acquire Elan Corporation PLC's Painkiller Prialt
Reuters -- Privately held Azur Pharma Limited entered into a definitive agreement with Elan Pharmaceuticals Inc, a unit of Elan Corp (ELN.N), to buy its painkiller Prialt.
FDA Approves Eisai Inc.'s Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS)
WOODCLIFF LAKE, N.J., March 11 /PRNewswire-FirstCall/ -- Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a five-day dosing regimen for Dacogen (decitabine) for Injection to treat patients with myelodysplastic syndromes (MDS), a group of bone marrow diseases that alter the production of functional blood cells.
The new outpatient dosing option provides...
Arena Pharmaceuticals, Inc. will Launch Lorcaserin with Partner or Alone
Reuters -- Arena Pharmaceuticals Inc expects to launch sales of its weight loss drug -- alone or with a partner -- within 12 weeks of U.S. regulatory approval, according to the company.
Women On Pill 'May Live Longer', Aberdeen University Study
LONDON (Reuters) - One of the world's largest studies of the contraceptive pill has found that women who have taken it can expect longer lives and are less likely to die from any cause, including cancer and heart disease.
Platelet-Rich Fibrin Matrix Shows No Impact On Clinical Outcomes, Study At American Academy of Orthopaedic Surgeons Conference Finds
Orthosupersite -- NEW ORLEANS One of the first prospective, randomized studies to evaluate the effect of platelet-rich fibrin matrix in arthroscopic rotator cuff repair shows that the product has no significant impact on clinical results and perioperative pain control.
AstraZeneca PLC Boosts Generic Exposure with Torrent Pharmaceuticals Ltd. Deal
The Sun News -- AstraZeneca PLC announced a supply partnership with India's Torrent Pharmaceuticals on Thursday, its first such link with a generic drugmaker as it seeks to boost its presence in emerging markets and counter patent losses on blockbuster medicines.
Despite Law, Drug Safety Still A Concern At FDA
WASHINGTON (Reuters) - Recent new powers have helped the U.S. Food and Drug Administration combat contaminated medications, counterfeit pills and other safety woes, but more work is needed to address lingering concerns about drug risks, FDA officials said on Wednesday.
Portola Pharmaceuticals, Inc.'s Announces CEO, M.D. to Retire
SOUTH SAN FRANCISCO, Calif., March 11 /PRNewswire/ -- Portola Pharmaceuticals, Inc. today announced that Charles Homcy, M.D., president and chief executive officer, will retire from his current position and assume the role of co-chairman of the board of directors, effective May 1, 2010. Dr. Homcy has served as president and CEO since 2003, when he co-founded the company. Chief Operating Officer William...
Patient Safety Reporting and Drug Label Accuracy Missing Vital Information, Expert From Memorial Sloan-Kettering Cancer Center Says
ScienceDaily (Mar. 11, 2010) A Perspective piece in the New England Journal of Medicine calls for change in the way researchers and pharmaceutical companies collect and report adverse symptom information in clinical trials submitted to the Food and Drug Administration (FDA), and how the FDA represents this information on drug labels.
200 Manchester Jobs Under Threat in AstraZeneca PLC Cuts
Crains Manchester Business -- More than 200 Manchester-based jobs are under threat at AstraZeneca after the pharmaceutical giant said previously announced plans to outsource some back office functions will affect its office in Chorlton-cum-Hardy.
Drug-Resistant Lice Respond Better to Ivermectin, Study in The New England Journal of Medicine
MedPage Today -- The antiparasitic drug ivermectin (Stromectol) is more effective than malathion lotion for treating infections of drug-resistant lice, a new industry-sponsored study found.
Local Pharma Can And Should Step Up Outsourcing Play
DNA -- In the late nineties, when big pharmaceutical companies starting feeling the burden of over-sized research units in the face of a dwindling pipeline of molecules, they started looking at ways to source manufacturing at lower costs and to farm out semi-skilled chemistry work to Indian companies.
Disease Cause Is Pinpointed With Genome, Baylor College of Medicine Study
WASHINGTON (Reuters) - Two studies published on Wednesday show it is possible to sequence the entire gene maps of families with inherited diseases and pinpoint the offending bit of DNA.
Experimental Drug That Mimics Thryoid Hormone Safely Lowers 'Bad' Cholesterol, Johns Hopkins University School of Medicine Study
ScienceDaily (Mar. 11, 2010) People whose "bad" cholesterol and risk of future heart disease stay too high despite cholesterol-lowering statin therapy can safely lower it by adding a drug that mimics the action of thyroid hormone. In a report published in the Mar. 11, issue of the New England Journal of Medicine, Johns Hopkins and Swedish researchers say an experimental drug called eprotirome lowered...
FDA Rules Out Thigh Fracture Link with Bisphosphonate, Including Medications such as Merck & Co., Inc.'s Fosamax
Reuters -- U.S. regulators said on Wednesday they have found no link between oral bisphosphonate osteoporosis medications such as Merck & Co Inc's (MRK.N) Fosamax and certain thigh bone fractures.
Hormone Thought to Slow Aging Associated With Increased Risk of Cancer Death, University of California, San Diego (UCSD) Study
ScienceDaily (Mar. 10, 2010) According to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM), older men with high levels of the hormone IGF-I (insulin-like growth factor 1) are at increased risk of cancer death, independent of age, lifestyle and cancer history.
Clark Johnson Appointed Neurologix, Inc. President and CEO
FORT LEE, N.J.--(BUSINESS WIRE)--Neurologix, Inc. (OTCBB:NRGX - News), a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, today announced that Clark A. Johnson, the Vice Chairman of Neurologix (the Company), has been appointed as the Companys President and Chief Executive Officer to replace John E. Mordock, who resigned.
Discovery of 'Fat' Taste Could Hold the Key to Reducing Obesity, Deakin University Study
Deakin University -- A newly discovered ability for people to taste fat could hold the key to reducing obesity, Deakin University health researchers believe.
Turning Tables On Prostate Cancer's Drug Resistance, University of California, San Diego (UCSD) Study
New Scientist -- DRUGS that keep prostate cancer at bay often stop working after a few years. That now appears to be because they prompt the growth of the very tumour cells they are meant to kill. It's not all bad news, though: blocking this growth pathway could buy time for men with drug-resistant tumours.
BioSante Pharmaceuticals, Inc. Says Leukemia Vaccine Shows Promise in Study
LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX - News) today announced positive results of a human clinical study that show that its GVAX Leukemia vaccine may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Gleevec (imatinib mesylate). All patients enrolled in the trial used Gleevec for...
Senetek PLC Embarks on New Strategic Direction; Company Completes $3.0 Million Financing; CEO and CFO Terminated in Connection with Financing
NAPA, Calif., March 10 /PRNewswire-FirstCall/ -- Senetek PLC today announced the closing of a Security Purchase Agreement, a Note and a Warrant Purchase Agreement DMRJ Group, LLC on March 4, 2010. DMRJ Group, LLC is a Delaware limited liability company affiliated with Platinum Partners Value Arbitrage Fund L.P., an accredited institutional investor with its investment manager headquartered in New...
Basilea Pharmaceutica: Johnson & Johnson Seeks Europe Rehearing on Skin Drug
MarketWatch -- Basilea Pharmaceutica AG, the Basel drugmaker, said on Thursday that a Johnson & Johnson subsidiary asked the European Committee For Medicinal Products for Human Use to re-examine its rejection of ceftobiprole to treat complicated skin and soft-tissue infections.
OXiGENE Announces $7.5 Million Financing
SOUTH SAN FRANCISCO, Calif., March 11, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN - News) (Stockholm:OXGN - News), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that it has entered into a definitive agreement with certain institutional investors to sell 6,578,945 shares of its Common Stock and separate series of warrants...
Beijing to Build Asia's Largest Pharmaceutical Base
Alibaba -- There are plans to build the largest global contract bio-pharmaceutical base in Asia in Beijing, with a total investment of about $120 million, Xinhua website reported on March 9.
Seaweed Extract May Hold Promise for Non-Hodgkin's Lymphoma Treatment, The Hashemite University Study
Newswise Seaweed extract may eventually emerge as a lymphoma treatment, according to laboratory research presented at the second AACR Dead Sea International Conference on Advances in Cancer Research: From the Laboratory to the Clinic, held here March 7-10, 2010.
UCB Group: Newly-Published Study Reinforces Role of Antiepileptic Drug Vimpat(R) (lacosamide) (C-V) as an Add-on Treatment that Significantly Reduces Partial-onset Seizures in Adults with Epilepsy
ATLANTA, March 11 /PRNewswire/ -- UCB today announced that the antiepileptic drug (AED) Vimpat (lacosamide) (C-V) demonstrated significantly fewer partial-onset seizures versus placebo in adults living with epilepsy, according to a Phase III clinical study published online in Epilepsia.
This study was one of three that supported the approval of Vimpat by the U.S. Food and Drug Administration...
University of Pittsburgh Medical Center Gets New Partners in Plan for Vaccine Factory
Pittsburgh Business Times -- An ambitious plan to build a vaccine factory in the Pittsburgh area is gaining momentum with the announcement Thursday of three new partners in the University of Pittsburgh Medical Center project.
Merck & Co., Inc.'s Stromectol Wipes Out Hard-to-Treat Lice, Study Finds
Bloomberg -- Merck & Co.s Stromectol tablet worked better than lotion at clearing up hard-to-treat head lice, a study found, as the infestations become increasingly resistant to current medicines.
Abbott Laboratories to Buy Facet Biotech for $722 Million
Provides Promising Biologic Intended to Treat Multiple Sclerosis and Compounds that Complement Abbott's Existing Diverse Oncology Program
ABBOTT PARK, Ill. and REDWOOD CITY, Calif., March 9 /PRNewswire-FirstCall/ -- Abbott (NYSE:ABT - News) and Facet Biotech Corporation (Nasdaq:FACT - News) announced today a definitive agreement for Abbott to acquire Facet, enhancing Abbott's early- and mid...
Amylin Pharmaceuticals, Inc., Eli Lilly and Company Diabetes Drug Faces Crucial FDA Decision
Dow Jones -- After years of anticipation, a long-acting version of diabetes drug Byetta, sold by Amylin Pharmaceuticals Inc. (AMLN) and Eli Lilly & Co. (LLY), faces a crucial Food and Drug Administration approval decision this week.
Novartis Corporation Takes Option on TRANSGENE Cancer Vaccine; Gets $10 Million, Milestones Could Reach $950 Million
Reuters -- Novartis has taken an exclusive option to develop Transgene's (TRNG.PA) cancer vaccine TG4010, but the deal fell short of investors' hopes, pulling the shares in the French biotechnology company down 12 percent.
Lacosamide Validated as Promising Therapy for Uncontrolled Partial-Onset Seizures, Barrow Neurological Institute, St. Joseph's Hospital, And Thomas Jefferson University Study
ScienceDaily (Mar. 9, 2010) A recent multi-center study has confirmed earlier study results that 400 mg/day of lacosamide provides a good balance of efficacy and tolerability for patients with uncontrolled partial-onset seizures (POS), and doses of 600mg/day may provide additional benefit for some patients.
FDA Advisory Committee Recommends Approval of InterMune, Inc.'s Esbriet(R) (pirfenidone) for Idiopathic Pulmonary Fibrosis
BRISBANE, Calif., March 9 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq:ITMN - News) announced today that the U.S. Food and Drug Administration's (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted 9-3 to recommend approval of Esbriet (pirfenidone) for the treatment of patients with idiopathic pulmonary fibrosis (IPF) to reduce decline in lung function.
IPF is a rare and...
Exelixis, Inc. Announces Restructuring; Reduces Workforce by Approximately 40%, or 270 Employees
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq:EXEL) today announced a restructuring as a consequence of its continued strategy to focus resources on the development of its key late-stage compounds. As its first priority, the company will aggressively advance XL184, XL147 and XL765, each of which is the subject of a large clinical development program. Additionally, Exelixis retains...
Skin Transplant Offers New Hope to Vitiligo Patients, Henry Ford Hospital Study
Henry Ford Hospital -- DETROIT - In the first study of its kind in the United States, Henry Ford Hospital showed that skin transplant surgery is safe and effective for treating vitiligo.
Cytokinetics, Inc.'s Lou Gehrig's Drug Gets Orphan Status
Reuters -- Cytokinetics Inc (CYTK.O) said its experimental drug for the treatment of a neurodegenerative disease received orphan drug status from U.S. health regulators, sending its shares up 5 percent in premarket trade.
University of California, San Diego (UCSD) Study Shows Potential for Using Algae to Produce Human Therapeutic Proteins
UCSD -- Pharmaceutical companies could substantially reduce the expense of costly treatments for cancer and other diseases produced from mammalian or bacterial cells by growing these human therapeutic proteins in algaerapidly growing aquatic plant cells that have recently gained attention for their ability to produce biofuels.
Merck & Co., Inc.'s Fosamax: Is Long Term Use of Bone Strengthening Drug Linked to Fractures?
Examiner -- Fosamax, a popular osteoporosis medication for which nearly 40 million prescriptions have been written, may be putting some at risk for spontaneous femur fractures. Fosamax is part of a group of drugs called bisphosphonates designed to make bones stronger.
Watson Pharmaceuticals, Inc., Takeda Pharmaceutical Co. Ltd. Resolve Actos Patent Litigation
MORRISTOWN, N.J., March 10 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI - News), today announced that it has reached a settlement agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding patent litigation related to Watson's generic equivalent version of Actos (Pioglitazone Hydrochloride) 15mg, 30mg and 45mg tablets. Under...
University of Missouri Researcher Presents Risk-free Treatment for Low Female Sexual Desire
University of Missouri -- COLUMBIA, Mo. According to the Journal of Sexual Medicine, people who engage in regular sexual activity gain several health benefits, such as longer lives, healthier hearts, lower blood pressure, and lower risk of breast cancer. However, approximately 33 percent of women may not receive these benefits due to low sexual desire. Also, the marriages of women with low sexual...
Bristol-Myers Squibb Company CEO's 2009 Compensation Down 22%
AP -- The chief executive of drugmaker Bristol-Myers Squibb Co., James Cornelius, received a 2009 compensation package valued by The Associated Press at $17 million, down 22 percent from 2008, due to the much lower value of his stock awards.
Affymax, Inc. Receives $5 Million Milestone Payment from Takeda Pharmaceutical Co. Ltd. on Initiation of Phase 3 Clinical Trials for Hematide in Japan
PALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq: AFFY - News) today announced that it has received a $5 million development milestone payment from Takeda Pharmaceutical Company as part of the companies exclusive global agreement to develop and commercialize Hematide, Affymaxs investigational drug for the treatment of anemia in chronic renal failure patients. The milestone was achieved...
University of Southern California Research Finds Shortcomings in Comparative Effectiveness Drug Research
Newswise An analysis by researchers at the Keck School of Medicine of the University of Southern California (USC) has found that only 32 percent of medication studies published in top medical journals compare the effectiveness of existing treatments. These studies, known as comparative effectiveness studies, help doctors know which therapies work best and under what circumstances they are most effective...
Neuropharm Group plc to Mull Voluntary Liquidation to Return Cash
Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical company focused on neurodevelopmental disorders, today provides an update to shareholders on developments in relation to the proposed sale or merger of the Company.
Neuropharm has been in discussions with a number of parties since it entered an offer period on 3 November 2009 and announced that it was pursuing a proposed sale or...
Transplant Drug Preserves Kidneys, Avoids Toxicity, Emory University Studies Suggest
Emory University -- The experimental drug belatacept can prevent graft rejection in kidney transplant recipients while better preserving kidney function when compared with standard immunosuppressive drugs, data from two international phase III clinical trials show.
Oculus Innovative Sciences, Inc. Receives First FDA Clearance for Microcyn(R)-Based HydroGel for Dermatology Market
PETALUMA, Calif.--(BUSINESS WIRE)--Oculus Innovative Sciences, Inc. (Nasdaq: OCLS - News), a commercial medical technology company that develops, manufactures and markets a family of products based upon the Microcyn Technology platform, today announced that it has received new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for new dermatology indications for Microcyn Skin and Wound...
BioSpace.com Featured News and Stories
Human Genome Sciences, Inc. Lung Cancer Drug, Mapatumumab in Combination with Chemotherapy Agents Fails to Improve Survival
ROCKVILLE, Md., Mar 17, 2010 (BUSINESS WIRE) -- Human Genome Sciences, Inc. /quotes/comstock/15*!hgsi/quotes/nls/hgsi (HGSI 31.25, -0.46, -1.45%) today announced the results of its randomized Phase 2 trial of mapatumumab (HGS-ETR1) in combination with the chemotherapy agents paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC).
The results showed...
Pfizer Inc. to Make Bid for Ratiopharm Today
Reuters -- Pfizer (PFE.N) will on Wednesday place an offer in the final round of bids for German generic drug maker Ratiopharm, a person briefed on the matter told Reuters on Wednesday.
The Medicines Company Expands a Nationwide Recall for Certain Lots of Cleviprex(R) That May Contain Particulate Matter
PARSIPPANY, NJ--(Marketwire - 03/17/10) - The Medicines Company (NASDAQ:MDCO - News) announced today that it is voluntarily expanding the recall of Cleviprex (clevidipine butyrate) injectable emulsion due to the potential presence of visible particulate matter which has been observed in some vials. Four (4) additional lots of Cleviprex are being recalled. The four additional Cleviprex lots are ...
Abraxis BioScience, Inc.: ABRAXANE Meets Primary Endpoint in Phase 3 Trial for Advanced Non-Small Cell Lung Cancer
LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABII - News) today announced that its randomized registrational Phase 3 clinical trial comparing ABRAXANE (protein-bound paclitaxel) with Taxol (paclitaxel) injection, both in combination with carboplatin, met the studys primary endpoint by demonstrating that ABRAXANE showed a significant improvement in overall response rate as compared...
U.S. FDA Warns Glenmark Pharmaceuticals on Unapproved Drug
Reuters -- Glenmark Pharmaceuticals Ltd (GLEN.BO) sold nitroglycerin tablets without approval from U.S. regulators, the Food and Drug Administration said in a letter released on Tuesday.
Novartis Pharma AG Reports Positive Results From Phase II LCZ696 Trial
Novartis Pharma has reported that its investigational product LCZ696, an angiotensin receptor neprilysin inhibitor (ARNI), has successfully completed its first large-scale clinical trial, highlighting the potential of the compound in the treatment of hypertension and other cardiovascular diseases.
LCZ696 is a novel-acting compound with distinctive chemical and biological properties; upon...
Prometheus Laboratories Inc. and Bayer Schering Pharma to Apply Novel Diagnostic Platform to Oncology Therapeutic Candidates; Eligible for Upfront and Milestone Payments up to $160 Million
SAN DIEGO, March 17 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the execution of a research collaboration and license agreement with Bayer Schering Pharma AG, Germany, a worldwide leading specialty pharmaceutical company. The collaboration partners Prometheus' proprietary oncology diagnostic platform with Bayer's broad oncology pipeline...
Unigene Laboratories, Inc. Receives Additional Capital in Debt Restructuring; Begins to Revamp Management Team
BOONTON, N.J.--(BUSINESS WIRE)--Unigene Laboratories, Inc. (OTCBB: UGNE, http://www.unigene.com) today announced that it has entered into an amended and restated financing agreement for $33 million three-year convertible senior secured term notes. At the closing, which is scheduled to occur today, Unigene will issue $33,000,000 of new convertible senior secured notes due in 2013, in exchange for approximately...
Molecular Insight Pharmaceuticals, Inc. Says Gets Going Concern Warning from Auditors
Reuters -- Molecular Insight Pharmaceuticals Inc posted a narrower-than-expected quarterly loss, but said its auditors have expressed doubts on its ability to continue as a going concern, partly due to recurring losses from its operations.
King Pharmaceuticals??, Inc. Unit, Alpharma Inc. to Pay $42.5 Million Over Kadian Claims
Reuters -- Alpharma Inc, a unit of King Pharmaceuticals (KG.N), has agreed to pay $42.5 million to resolve allegations that it gave kickbacks to doctors to prescribe the pain drug Kadian and misrepresented its safety and effectiveness, the Justice Department said on Tuesday.
Sanofi-Aventis (France) Says World Health Organization Suspension of Shan5 Is Precautionary Measure
Bloomberg -- Sanofi-Aventis SA said the World Health Organizations temporary suspension of its Shan5 vaccine is a precautionary measure pending outcome of an investigation of vaccine quality.
U.S. FDA Accepts New Drug Application For Once-Daily Fixed Dose Combination Of Bristol-Myers Squibb Company And AstraZeneca PLC's Onglyza(TM) (Saxagliptin) And Extended Release Metformin For The Treatment Of Type 2 Diabetes Mellitus In Adults
PRINCETON, N.J. & WILMINGTON, Del.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for an investigational fixed dose combination of ONGLYZA (saxagliptin), a dipeptidyl peptidase-4 (DPP4) inhibitor, and metformin HCl extended-release tablets as...
Acura Pharmaceuticals, Inc. and King Pharmaceuticals??, Inc. Release: FDA Schedules Joint Advisory Committee Meeting for Acurox(R)
PALATINE, Ill. and BRISTOL, Tenn., March 17, 2010 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (Nasdaq:ACUR) and King Pharmaceuticals, Inc. (NYSE:KG) today announced that the U.S. Food and Drug Administration ("FDA") has publically announced the scheduling of an April 22, 2010 Advisory Committee meeting to discuss the New Drug Application ("NDA") for Acurox (oxycodone HCl and niacin) Tablets and...
Chelsea Therapeutics, Inc. Reports Findings From Northera 24-Hour Blood Pressure Monitoring Study
CHARLOTTE, N.C., March 17, 2010 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) reported findings from Study 305, a study evaluating the effect of Northera (Droxidopa), an investigational agent being studied for the treatment of neurogenic orthostatic hypotension (NOH), on patients' 24-hour blood pressure (BP) profile.
Nabi Biopharmaceuticals Initiates Second Phase III Study for NicVAX as an Aid to Smoking Cessation and Long-term Abstinence
ROCKVILLE, Md., March 17, 2010 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) announced that it has initiated the second of two pivotal Phase III clinical trials for NicVAX (Nicotine Conjugate Vaccine), the company's innovative and proprietary vaccine to treat nicotine addiction and prevent smoking relapse. The FDA has agreed with Nabi on the study design, protocol and end points through...
Zogenix, Inc. Initiates Pivotal Phase 3 Clinical Trial for Novel Formulation of Oral Controlled-Release Hydrocodone
SAN DIEGO, March 17 /PRNewswire/ -- Zogenix, Inc. ("Zogenix"), a privately held pharmaceutical company, announced that it has initiated a pivotal Phase 3 clinical trial with ZX002, a novel, oral, controlled-release formulation of hydrocodone without acetaminophen. ZX002 is being developed for the treatment of moderate to severe pain in individuals who require around-the-clock opioid therapy...
Pfizer Inc. Release: Phase III Study Shows Prevenar 13* Is Immunogenic In Young Children Previously Vaccinated With Prevenar*
NEW YORK--(BUSINESS WIRE)--According to results from a Phase III safety and immunogenicity study presented today, Prevenar 13* (Pneumococcal polysaccharide conjugate vaccine, [13-valent, adsorbed]) was shown to be immunogenic and generally well tolerated in healthy young children who had received at least three prior doses of Prevenar* (Pneumococcal Saccharide Conjugated Vaccine, Adsorbed). These data...
Trophos Completes Patient Enrolment in Pivotal Phase 3 Efficacy Study of Olesoxime in Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease)
Marseille, France, March 17, 2010 - Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announced today the completion of patient enrolment with over 500 patients recruited into the pivotal phase 3 efficacy study of olesoxime in Amyotrophic Lateral Sclerosis...
Acucela Inc. and Otsuka Pharmaceutical Co., Ltd. Receive FDA Fast Track Designation for ACU-4429 in Patients with Dry AMD
BOTHELL, Wash. & TOKYO--(BUSINESS WIRE)--Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, and Otsuka Pharmaceutical Co., Ltd., today announced that they have received Fast Track designation from the U.S. Food and Drug Administration (FDA) for ACU-4429, an investigational oral treatment for dry age-related macular degeneration (dry...
Human Genome Sciences, Inc. Announces Results of Randomized Phase 2 Trial of Mapatumumab in Non-Small Cell Lung Cancer
ROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced the results of its randomized Phase 2 trial of mapatumumab (HGS-ETR1) in combination with the chemotherapy agents paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC).
Agendia BV to Play Pivotal Role in ISPY-2 Trial for Breast Cancer
12 Cancer Drugs Tested, 20 Leading U.S. Cancer Centers Involved HUNTINGTON BEACH, California and AMSTERDAM, March 17, 2010 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, announced today it will participate in the highly anticipated I-SPY 2 TRIAL for breast cancer, set to launch at the first of nearly twenty research sites. I-SPY 2 is an exciting and groundbreaking...
Allon Therapeutics, Inc. Receives European Orphan Drug Status for Davunetide
VANCOUVER, BRITISH COLUMBIA--(Marketwire - March 17, 2010) - Allon Therapeutics Inc. (TSX: NPC) announced today that its lead neuroprotective drug candidate, davunetide, has been granted Orphan Drug Status in the European Union (EU) for the treatment of...
Protalix Biotherapeutics Initiates a Phase I Clinical Trial of Acetylcholinesterase for Biodefense Indications
CARMIEL, Israel, March 17 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX) announced today that it has initiated a phase I clinical trial of PRX-105, the Company's plant cell expressed pegylated recombinant human acetylcholinesterase product candidate in development for biodefense indications. The trial is designed to study the safety of PRX-105 by administering... PAREXEL International Completes Early Phase Study Requiring Genotyping of More Than 10,000 Potential Participants
BOSTON, March 17 /PRNewswire-FirstCall/ -- PAREXEL International Corporation , a leading global biopharmaceutical services provider, today announced that it has completed a large and complex pharmacogenetics-based early phase study. The study was conducted in a healthy volunteer population of poor metabolizers of Cytochrome P450 2D6 (CYP2D6), an important enzyme involved in the metabolism... Alkermes Announces Initiation of Multidose Phase 1 Clinical Study of ALKS 37 for the Treatment of Opioid-Induced Constipation
CorMatrix Cardiovascular Announces Publication of Pre-Clinical Data in
ATLANTA, March 16 /PRNewswire/ -- CorMatrix Cardiovascular, Inc., a medical device company dedicated to developing and delivering unique extracellular matrix (ECM) biomaterial devices that harness the body's innate ability to repair damaged cardiovascular tissue, announced today that investigators from the Mercer University School of Medicine, Emory University and CorMatrix Cardiovascular, Inc... Idera Pharmaceuticals, Inc. Announces Acceptance of IMO-2125 Abstracts for Presentation at EASL Annual Meeting
Vertex Pharmaceuticals (MA) Announces Acceptance of Telaprevir and VX-222 Abstracts for Presentation at Annual Meeting
Bionor Immuno Release: New Path to Therapeutic HIV Vaccine Discovered by Studying Immunologic Profile of Rare HIV Controllers
OSLO, NORWAY--(Marketwire - March 17, 2010) -
WALTHAM, Mass.--(BUSINESS WIRE)--Alkermes, Inc. (NASDAQ: ALKS) today announced the initiation of a multidose phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the effects of opioid agonists on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC). The randomized, double-blind, placebo-controlled, repeat...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that two abstracts related to its Toll-like Receptor 9 (TLR9) agonist, IMO-2125, were accepted for presentation at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria, April 14-18, 2010. IMO-2125 is being evaluated for potential applications in chronic hepatitis...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that multiple abstracts related to the hepatitis C virus (HCV) protease inhibitor telaprevir and the HCV polymerase inhibitor VX-222 were accepted for presentation at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria, April 14-18, 2010. The accepted...
Search Powered By Google
Yet, the stock's price chart suggests that bottom feeding might not be a bad idea one of these weeks. The news is bad, true, but the news around cheap stocks usually is bad. I watched the stock fall from $45 in 2004, patiently waited for some kind of base to show up, then built a position in 2007 and 2008 at a cost basis of $12.98. Boy, did that look cheap.
Nobody knows exactly how Intermune's (ITMN) lung-disease treatment works. But that didn't stop investors from sending the company's shares soaring March 10 as an FDA panel recommended its lung-disease treatment, pirfenidone, for approval. The vote of confidence from the FDA's Pulmonary-Allergy Drugs Advisory Committee sparked buyout speculation on Wall Street, which sees gold in orphan drugs, such as pirfenidone, with the potential to sell to niche markets for high prices and retain extended patent protection.
Tom Lydon